Celularity IncNASDAQ:CELUNASDAQ FSI:E. Delinquent (Issuer missed regulatory filing deadline)
- LAST PRICE3.0000
- TODAY'S CHANGE (%)-0.0500 (-1.6393%)
- Bid / Lots2.9900/ 1
- Ask / Lots3.9900/ 1
- Open / Previous Close3.0600 / 3.0500
- Day Range
- 52 Week Range
- Volume32,876
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CELU |
|---|---|---|
| 09:32 ET | 634 | 3.07 |
| 09:34 ET | 400 | 3.075 |
| 09:38 ET | 1415 | 3.105 |
| 09:39 ET | 1000 | 3.125 |
| 09:41 ET | 300 | 3.1 |
| 09:48 ET | 300 | 3.15 |
| 09:50 ET | 670 | 3.08 |
| 09:52 ET | 200 | 3.05 |
| 09:54 ET | 200 | 3.1 |
| 09:56 ET | 200 | 3.08 |
| 09:59 ET | 657 | 3.04 |
| 10:01 ET | 300 | 3.03 |
| 10:12 ET | 843 | 3.1081 |
| 10:14 ET | 100 | 3.03 |
| 10:24 ET | 200 | 3.2253 |
| 10:28 ET | 2934 | 3.14 |
| 10:37 ET | 380 | 3.0673 |
| 10:39 ET | 200 | 3.04 |
| 10:51 ET | 101 | 3.05 |
| 10:53 ET | 548 | 3.05 |
| 11:06 ET | 257 | 3.2194 |
| 11:13 ET | 642 | 3.18 |
| 11:24 ET | 200 | 3.09 |
| 11:27 ET | 100 | 3.09 |
| 11:29 ET | 100 | 3.06 |
| 11:31 ET | 101 | 3.135 |
| 11:33 ET | 400 | 3.13 |
| 11:36 ET | 200 | 3.135 |
| 11:38 ET | 100 | 3.05 |
| 11:51 ET | 100 | 3.135 |
| 12:36 ET | 100 | 3.135 |
| 12:39 ET | 410 | 3.05 |
| 12:41 ET | 101 | 3.05 |
| 12:43 ET | 101 | 3.05 |
| 12:48 ET | 200 | 3.05 |
| 12:52 ET | 101 | 3.05 |
| 12:54 ET | 1000 | 3.1 |
| 12:56 ET | 200 | 3.05 |
| 12:57 ET | 201 | 3.05 |
| 12:59 ET | 201 | 3.08 |
| 01:06 ET | 100 | 3.05 |
| 01:08 ET | 100 | 3.05 |
| 01:12 ET | 101 | 3.05 |
| 01:14 ET | 101 | 3.05 |
| 01:15 ET | 201 | 3.05 |
| 01:19 ET | 101 | 3.05 |
| 01:21 ET | 200 | 3.14 |
| 01:26 ET | 1865 | 3.1675 |
| 01:30 ET | 500 | 3.11 |
| 01:32 ET | 100 | 3.05 |
| 01:33 ET | 400 | 3.03 |
| 01:48 ET | 100 | 3.07 |
| 02:00 ET | 400 | 3.0446 |
| 02:04 ET | 200 | 3.0807 |
| 02:20 ET | 100 | 3.075 |
| 02:26 ET | 200 | 3.075 |
| 02:38 ET | 100 | 3.1019 |
| 02:40 ET | 100 | 3.065 |
| 02:44 ET | 100 | 3.077 |
| 02:49 ET | 100 | 3.07 |
| 02:54 ET | 200 | 3.04 |
| 03:14 ET | 100 | 3.07 |
| 03:25 ET | 1099 | 3.02 |
| 03:27 ET | 717 | 3.01 |
| 03:32 ET | 100 | 3.03 |
| 03:50 ET | 100 | 3.0194 |
| 03:52 ET | 100 | 3.04 |
| 03:54 ET | 200 | 3.024 |
| 03:57 ET | 136 | 3 |
May 14, 2024
Apr 22, 2024
Celularity Inc. to Host Investor and Analyst Research & Development Day, from 8:00AM ET on Monday Apr 22, 2024 by Dow Jones
8:00AM ET on Monday Apr 22, 2024 by Dow Jones
Apr 19, 2024
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing, from 5:30PM ET on Friday Apr 19, 2024 by Dow Jones
5:30PM ET on Friday Apr 19, 2024 by Dow Jones
Apr 18, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Celularity Inc | 65.3M | -0.3x | --- |
Turnstone Biologics Corp | 61.5M | -0.8x | --- |
Carisma Therapeutics Inc | 58.6M | -0.7x | --- |
Aligos Therapeutics Inc | 53.8M | -0.5x | --- |
Prenetics Global Ltd | 70.9M | -1.3x | --- |
Gritstone bio Inc | 85.5M | -0.5x | --- |
Company Information
Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), natural killer, cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CYCART-19, CYCART-201, CYNK-001, CYNK-301, CYNK-302, APPL-001, and pEXO-001. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the cluster of differentiation 19. pExo-001 is developed for the treatment of osteoarthritis. APPL-001 is developed for the treatment of Crohn’s disease.
Contact Information
- Headquarters
- 170 Park AveFLORHAM PARK, NJ, United States 07932
- Phone
- 908-768-2170
- Fax
- 302-636-5454
Executives
- Chairman of the Board, Chief Executive Officer
- Robert Hariri
- Chief Financial Officer
- David Beers
- President - Degenerative Disease
- Stephen Brigido
- Senior Executive Vice President, Chief Administrative Officer, General Manager
- John Haines
- Director
- Shiu Fei Ling
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $65.3M |
|---|---|
Revenue (TTM) | $14.8M |
Shares Outstanding | 21.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.43 |
EPS | $-10.51 |
Book Value | $13.36 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 4.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,272.09% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
